Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects

Clinical Drug Investigation

Volumn 31, Issue 12, 2011, Pages 839-851

  Veltkamp, Stephan A ^a   Kadokura, Takeshi ^b   Krauwinkel, Walter J J ^a   Smulders, Ronald A ^a  

^a Astellas Pharma Global Development   (Netherlands)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Antihyperglycaemics; Ipragliflozin; Pharmacology; Sodium glucose transporter 2 inhibitors; Sodium glucose transporter 2 inhibitors; Type 2 diabetes mellitus

Indexed keywords

ASP 1941; GLUCOSE; IPRAGLIFLOZIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; APPETITE; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSURIA; FATIGUE; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; INTESTINE SOUND; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUTH ULCER; MYALGIA; PHARMACOLOGICAL PARAMETERS; POLLAKISURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SYNCOPE; URINARY EXCRETION;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE DETERMINATION; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; GLUCOSE; GLUCOSIDES; GLYCOSURIA; HEART RATE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLACEBOS; SEX FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; SYMPORTERS; THIOPHENES; YOUNG ADULT;

EID: 80155181454     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11594330-000000000-00000     Document Type: Article

References (40)

1. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 2005; 36: 197-209 (Pubitemid 40755133)
2. Moss SE, Klein R, Klein BE, et al. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 1994; 154: 2473-9 (Pubitemid 24348159)
3. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258-68
4. Nathan DM, Buse JB, Davidson MB, et al., American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203
5. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-42 (Pubitemid 38101606)
6. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010; 95: 34-42
7. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376: 419-30
8. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009; 53: 875-83
9. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001; 280: F10-8
10. Neumiller JJ, White Jr JR, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010; 70: 377-85
11. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008; 62: 1279-84 (Pubitemid 351977622)
12. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011; 22: 104-12
13. Turk E, Zabel B, Mundlos S, et al. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature 1991; 350: 354-6 (Pubitemid 21912230)
14. Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. JAmSoc Nephrol 2003; 14: 2873-82 (Pubitemid 37305650)
15. Vestri S, Okamoto MM, de Freitas HS, et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 2001; 182: 105-12 (Pubitemid 32641748)
16. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-34 (Pubitemid 43334332)
17. Freitas HS, Anhê GF, Melo KF, et al. Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 2008; 149: 717-4
18. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650-7
19. Patel AK, Fonseca V. Turning glucosuria into a therapy: efficacy and safety with SGLT2 inhibitors. Curr Diab Rep 2010; 10: 101-7
20. Kurosaki E, Tahara A, Yokono M, et al. In vitro and in vivo pharmacological properties of ASP1941, a novel, potent and selective SGLT2 inhibitor [abstract no. 0570-P]. American Diabetes Association, 70th Scientific Sessions; 2010 June 25-29; Orlando (FL)
21. Takasu T, Tahara A, Yokono M, et al. ASP1941, a novel, potent and selective SGLT2 inhibitor, improves hemoglobin A1c and symptoms of diabetes in animal models [abstract no. 0562-P]. American Diabetes Association, 70th Scientific Sessions; 2010 June 25-29; Orlando (FL)
22. Data on file. Internal Report 1941-ME-0040. Identification of ASP1941 metabolites in humans, 12 March 2010. Astellas Pharma Inc., Kashima, Osaka
23. Data on file. Internal Report 1941-PH-0029. Inhibitory activities of human metabolites of ASP1941 on cellular uptake of methyl-a-D-glucopyranoside (AMG) in human Na+-glucose cotransporter (SGLT)-expressing cells, 12 April 2010. Astellas Pharma Inc., Tsukuba, Ibaraki
24. Data on file. Internal report 1941-ME-0045. Correlation of ASP1941 metabolic activity with UGT enzyme activities in human liver microsomes, 29 March 2010. Astellas Pharma Inc., Kashima, Osaka
25. Data on file. Internal Report 1941-ME-0055. Inhibitory effects of ASP1941 on the activity of UDP-glucuronosyltransferases using human livermicrosomes, 09 December 2010. XenoTech, LLC, Lenexa (KS)
26. Data on file. Internal Report 1941-ME-0039. Timedependent inhibitory effects of ASP1941 on the activity of CYP isozymes using human liver microsomes, 16 October 2009. Sekisui Medical Co., Ltd, Muramatsu, Ibaraki
27. Tassi C, Mancuso F, Feligioni L, et al. Expression modes of urinary N-acetyl-beta-D-glucosaminidase in patients with chronic renal insufficiency. Clin Chim Acta 2004; 346: 129-33 (Pubitemid 38901043)
28. Lisowska-Myjak B. Serum and urinary biomarkers of acute kidney injury. Blood Purif 2010; 29: 357-65
29. Data on file. Internal Report 1941-ME-0009. Validation of a LC-MS/MS method for the determination of ASP1941 in human plasma, 04 December 2007. Astellas Pharma Europe B.V., Leiderdorp
30. Data on file. Internal Report 1941-ME-0010. Validation of a LC-MS/MS method for the determination of ASP1941 in human urine, 04 December 2007. Astellas Pharma Europe B.V., Leiderdorp
31. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, doubleblind, placebo-controlled trial. Lancet 2010; 375: 2223-33
32. Sobel JD. Candidal vulvovaginitis. Clin Obstet Gynecol 1993; 36: 153-65 (Pubitemid 23065141)
33. Geerlings SE, Stolk RP, CampsMJ, et al., Diabetes Women Asymptomatic Bacteriuria Utrecht Study Group. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000; 23: 1737-41
34. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51 (5): 1145-9 (Pubitemid 351480378)
35. Komoroski B,VachharajaniN, BoultonD, et al.Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520-6
36. Schwartz S, Klasen S, Kowalski D, et al. ASP1941, a novel and selective inhibitor of sodium-glucose co-transporter 2 (SGLT2), reduces fasting plasma glucose in patients with type 2 diabetes mellitus [abstract no. 0566-P]. American Diabetes Association, 70th Scientific Sessions; 2010 June 25-29; Orlando (FL)
37. Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-9
38. Kapur AR, O'Connor-Semmes RL, Hussey EK, et al. First human dose escalation study with remogliflozin etabonate (RE) in healthy subjects and in subjects with type 2 diabetes mellitus [abstract no. 509-P]. American Diabetes Association, 69th Scientific Sessions; 2009 June 5-9; New Orleans (LA)
39. Boyle PJ, Zrebiec J. Physiological and behavioral aspects of glycemic control and hypoglycemia in diabetes. South Med J 2007; 100: 175-82 (Pubitemid 46213761)
40. Landau BR, Wahren J, Chandramouli V, et al. Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 1996; 98: 378-85 (Pubitemid 26255737)